STAKEHOLDERS’ ANALYSIS TOOLS TO SUPPORT THE OPEN INNOVATION PROCESS MANAGEMENT – CASE STUDY

Open Innovation (OI) is a strategy to buster R&D productivity that introduces business flexibility via an open approach, either to external ideas or to collaborative work. Considering that the OI concept changes the perception of value creation and raises the number of stakeholders that contribute to a single project, stakeholders’ analysis seems to be adequate to identify the network partners involved in a project for management purposes. The aim in this paper is to propose a set of tools for stakeholders’ analysis, directed to the identification, prioritization and categorization of stakeholders in an OI management environment. The tools were tested, based on a qualitative approach, in a case study in the Brazilian Pharmaceutical industry. The study led to the understanding of the relationship’s importance and correlation of stakeholders in four representative pharmaceutical organizations that adhered to the OI strategy. The set of tools were useful to access the incoherence between the importance attributed to a given stakeholder and the kind of collaboration he shares. It revealed that the intensity of the relationships between them is different from a company to another.

[1]  Basil Achilladelis,et al.  The dynamics of technological innovation : the case of the pharmaceutical industry , 2001 .

[2]  N. Sakkab,et al.  Connect and Develop : Inside Procter & Gamble's New Model for Innovation , 2006 .

[3]  Esther F. Schmid,et al.  Is pharmaceutical R&D just a game of chance or can strategy make a difference? , 2004, Drug discovery today.

[4]  N. Sakkab,et al.  Implementing Open Innovation , 2007 .

[5]  Jan Terje Karlsen,et al.  Project Stakeholder Management , 2002 .

[6]  John Dixon,et al.  Vertical disintegration: a strategy for pharmaceutical businesses in 2009? , 2009, Nature Reviews Drug Discovery.

[7]  M. Kendall Elementary Statistics , 1945, Nature.

[8]  Mark J. Belsey,et al.  Drug developer strategies to boost competitiveness , 2007, Nature Reviews Drug Discovery.

[9]  H. Chesbrough The Era of Open Innovation , 2003 .

[10]  C. Tralau-Stewart,et al.  Drug discovery: new models for industry-academic partnerships. , 2009, Drug discovery today.

[11]  Janet M. Dewdney,et al.  Putting a new spin on R&D assets in the pharmaceutical industry , 1998 .

[12]  Timothy W. Nix,et al.  Strategies for assessing and managing organizational stakeholders , 1991 .

[13]  S. Mazzocchi Open Innovation: The New Imperative For Creating and Profiting From Technology , 2004 .

[14]  M. Dodgson,et al.  The Role of Technology in the Shift Towards Open Innovation: The Case of Procter & Gamble , 2006 .

[15]  N. Cohen,et al.  Open innovation networks between academia and industry: an imperative for breakthrough therapies , 2009, Nature Medicine.

[16]  B. Dousset Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry , 2005 .

[17]  Henry Chesbrough,et al.  Open Innovation: The New Imperative for Creating and Profiting from Technology , 2003 .

[18]  G. Hayward Managing Innovation: Integrating Technological, Market and Organizational Change , 1998 .

[19]  Paul G. Hoel,et al.  Elementary statistics , 1971 .

[20]  R. Freeman Strategic Management: A Stakeholder Approach , 2010 .

[21]  Ian Sommerville,et al.  Requirements Engineering: Processes and Techniques , 1998 .

[22]  Ronald K. Mitchell,et al.  Toward a Theory of Stakeholder Identification and Salience: Defining the Principle of who and What Really Counts , 1997 .

[23]  Jing Zhang,et al.  Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry , 2007 .

[24]  R. Rothwell Towards the Fifth‐generation Innovation Process , 1994 .

[25]  Shabbir T. Anik Drug development: A new map for creating sustainable competitive advantages , 2002 .